Jeantet advises investment funds Orbimed and MorningSide Ventures in connection with €39 million financing of Enyo Pharma
Paris, January 8, 2024 – Jeantet advised investment funds OrbiMed and Morningside Ventures in connection with the Series C financing of French biopharmaceutical company ENYO Pharma. ENYO Pharma, a clinical-stage biopharmaceutical company developing proprietary medicines to improve quality of life and avoid end-stage renal failure and dialysis in patients with kidney disease, announced on January […]
Paris | CORPORATE – M&A – PRIVATE EQUITY